Published in Cancer Res on January 01, 1999
A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A (2004) 6.84
Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev (2010) 2.97
Overview: ABC transporters and human disease. J Bioenerg Biomembr (2001) 2.60
Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer (2003) 2.33
Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J (2005) 2.03
ABCG2: a perspective. Adv Drug Deliv Rev (2008) 1.97
Recent progress in tumor pH targeting nanotechnology. J Control Release (2008) 1.94
Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer (2010) 1.85
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol (2012) 1.65
Regulation of ABCG2 expression at the 3' untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line. Mol Cell Biol (2008) 1.58
Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res (2010) 1.55
The chemical defensome: environmental sensing and response genes in the Strongylocentrotus purpuratus genome. Dev Biol (2006) 1.54
Increased Nrf2 activation in livers from Keap1-knockdown mice increases expression of cytoprotective genes that detoxify electrophiles more than those that detoxify reactive oxygen species. Toxicol Sci (2009) 1.54
Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol (2008) 1.46
Distribution and physiology of ABC-type transporters contributing to multidrug resistance in bacteria. Microbiol Mol Biol Rev (2007) 1.46
ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene (2011) 1.42
Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J Membr Biol (2005) 1.39
Improving cancer chemotherapy with modulators of ABC drug transporters. Curr Drug Targets (2011) 1.35
Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells. Mol Cancer Res (2008) 1.34
Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr Drug Metab (2010) 1.33
Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Invest (2000) 1.32
Drug transporters in the human blood-placental barrier. Br J Pharmacol (2009) 1.30
Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin J Cancer (2011) 1.30
ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood (2006) 1.27
Aberrant promoter methylation of the ABCG2 gene in renal carcinoma. Mol Cell Biol (2006) 1.26
MRP subfamily transporters and resistance to anticancer agents. J Bioenerg Biomembr (2001) 1.24
Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol (2011) 1.21
BCRP/ABCG2 in the placenta: expression, function and regulation. Pharm Res (2008) 1.17
Transplantable hematopoietic stem cells in human fetal liver have a CD34(+) side population (SP)phenotype. J Clin Invest (2001) 1.16
Pharmacophore-based discovery of ligands for drug transporters. Adv Drug Deliv Rev (2006) 1.15
Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior. Nat Genet (2012) 1.15
Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2. Mol Cancer Ther (2009) 1.14
Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer. Oncotarget (2014) 1.13
Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter. Mol Cancer Ther (2007) 1.13
The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr (2001) 1.13
Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function. PLoS One (2009) 1.13
Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. Drug Resist Updat (2012) 1.12
Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal (2009) 1.11
MicroRNAs as therapeutic targets in chemoresistance. Drug Resist Updat (2013) 1.11
ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut (2003) 1.10
Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations. Pharm Res (2008) 1.09
The challenge of exploiting ABCG2 in the clinic. Curr Pharm Biotechnol (2011) 1.06
The role of half-transporters in multidrug resistance. J Bioenerg Biomembr (2001) 1.04
Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J (2005) 1.03
The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2). Br J Pharmacol (2007) 1.03
ABCG2 is associated with HER-2 expression, lymph node metastasis and clinical stage in breast invasive ductal carcinoma. Diagn Pathol (2011) 1.01
Glutathione transport is a unique function of the ATP-binding cassette protein ABCG2. J Biol Chem (2010) 1.01
Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells. Curr Eye Res (2009) 1.00
A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport. Biochem J (2003) 1.00
Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance. Chem Rev (2014) 1.00
MRP9, an unusual truncated member of the ABC transporter superfamily, is highly expressed in breast cancer. Proc Natl Acad Sci U S A (2002) 1.00
Gastric carcinogenesis and the cancer stem cell hypothesis. Gastric Cancer (2010) 1.00
Antitumor agents. 280. Multidrug resistance-selective desmosdumotin B analogues. J Med Chem (2010) 0.99
ATP-binding cassette efflux transporters in human placenta. Curr Pharm Biotechnol (2011) 0.98
ABC transporters and their role in nucleoside and nucleotide drug resistance. Biochem Pharmacol (2012) 0.98
Membrane topology of the human breast cancer resistance protein (BCRP/ABCG2) determined by epitope insertion and immunofluorescence. Biochemistry (2008) 0.97
Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin Ther Targets (2009) 0.96
Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2. Biochemistry (2010) 0.96
Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance. Cancers (Basel) (2014) 0.95
Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines. J Cancer Res Clin Oncol (2008) 0.95
Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter. Br J Pharmacol (2006) 0.94
Interleukin-1 beta and tumor necrosis factor-alpha increase ABCG2 expression in MCF-7 breast carcinoma cell line and its mitoxantrone-resistant derivative, MCF-7/MX. Inflamm Res (2009) 0.94
The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding. Protein Sci (2006) 0.94
Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation. Br J Cancer (2004) 0.92
Structure-activity relationships and quantitative structure-activity relationships for breast cancer resistance protein (ABCG2). AAPS J (2009) 0.92
Environmental sensing and response genes in cnidaria: the chemical defensome in the sea anemone Nematostella vectensis. Cell Biol Toxicol (2008) 0.92
Adverse Cell Culture Conditions Mimicking the Tumor Microenvironment Upregulate ABCG2 to Mediate Multidrug Resistance and a More Malignant Phenotype. ISRN Oncol (2012) 0.91
Mutational studies of G553 in TM5 of ABCG2: a residue potentially involved in dimerization. Biochemistry (2006) 0.91
Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2. Oncotarget (2014) 0.91
Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols. J Hematol Oncol (2012) 0.90
Cooperation of cancer stem cell properties and epithelial-mesenchymal transition in the establishment of breast cancer metastasis. J Oncol (2010) 0.90
Molecular mechanisms of drug resistance in single-step and multi-step drug-selected cancer cells. Methods Mol Biol (2010) 0.90
Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: critical role of methoxylation in both inhibition potency and cytotoxicity. J Med Chem (2012) 0.89
Effect of cysteine mutagenesis on the function and disulfide bond formation of human ABCG2. J Pharmacol Exp Ther (2008) 0.89
BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure. Br J Cancer (2009) 0.89
Hormonal regulation of BCRP expression in human placental BeWo cells. Pharm Res (2007) 0.89
Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. Int J Oncol (2014) 0.89
Arginine 383 is a crucial residue in ABCG2 biogenesis. Biochim Biophys Acta (2009) 0.88
Role of basic residues within or near the predicted transmembrane helix 2 of the human breast cancer resistance protein in drug transport. J Pharmacol Exp Ther (2010) 0.88
Multidrug transporter activity in lymphocytes. Br J Pharmacol (2004) 0.88
Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2. Mol Med (2012) 0.87
Role of ABC transporters in cancer chemotherapy. Chin J Cancer (2012) 0.87
New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies. J Exp Clin Cancer Res (2015) 0.87
Intestinal ciprofloxacin efflux: the role of breast cancer resistance protein (ABCG2). Drug Metab Dispos (2011) 0.85
ABC transporters in fish species: a review. Front Physiol (2014) 0.85
Identification and characterization of the major alternative promoter regulating Bcrp1/Abcg2 expression in the mouse intestine. Biochim Biophys Acta (2011) 0.85
Fluorescence resonance energy transfer (FRET) analysis demonstrates dimer/oligomer formation of the human breast cancer resistance protein (BCRP/ABCG2) in intact cells. Int J Biochem Mol Biol (2010) 0.85
Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines. J Cancer Res Clin Oncol (2010) 0.84
ABCG2 is not able to catalyze glutathione efflux and does not contribute to GSH-dependent collateral sensitivity. Front Pharmacol (2013) 0.84
Circumvention of multi-drug resistance of cancer cells by Chinese herbal medicines. Chin Med (2010) 0.84
Transcription factors Sp1 and Sp3 regulate expression of human ABCG2 gene and chemoresistance phenotype. Mol Cells (2013) 0.84
Blood brain barrier: a challenge for effectual therapy of brain tumors. Biomed Res Int (2015) 0.82
Key Role of Human ABC Transporter ABCG2 in Photodynamic Therapy and Photodynamic Diagnosis. Adv Pharmacol Sci (2010) 0.82
EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors. PLoS One (2012) 0.82
A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo. Oncotarget (2015) 0.82
Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo. Oncotarget (2015) 0.81
Hydrogen-bond formation of the residue in H-loop of the nucleotide binding domain 2 with the ATP in this site and/or other residues of multidrug resistance protein MRP1 plays a crucial role during ATP-dependent solute transport. Biochim Biophys Acta (2006) 0.81
Genetic variation: effect on prostate cancer. Biochim Biophys Acta (2014) 0.81
Antipsychotic drugs inhibit the function of breast cancer resistance protein. Basic Clin Pharmacol Toxicol (2008) 0.81
Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes. Invest New Drugs (2006) 0.81
Identification of the cystic fibrosis gene: chromosome walking and jumping. Science (1989) 21.46
An information-intensive approach to the molecular pharmacology of cancer. Science (1997) 11.43
A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat Genet (1997) 10.93
Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell (1996) 7.86
A closely linked genetic marker for cystic fibrosis. Nature (1985) 7.85
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83
Cell-cycle control of c-myc but not c-ras expression is lost following chemical transformation. Cell (1984) 6.53
Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration. Science (1997) 6.00
Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem (1997) 5.51
Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes. Am J Hum Genet (1998) 5.24
The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet (1996) 4.36
Mechanism of met oncogene activation. Cell (1986) 4.20
Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc Natl Acad Sci U S A (1987) 3.99
Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science (1998) 3.60
The human met oncogene is related to the tyrosine kinase oncogenes. Nature (1985) 3.46
Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst (1999) 3.41
p53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nat Cell Biol (2000) 3.05
Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene (1999) 3.01
Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat (1995) 2.91
Retinitis pigmentosa caused by a homozygous mutation in the Stargardt disease gene ABCR. Nat Genet (1998) 2.87
Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat Genet (2001) 2.84
ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport. Proc Natl Acad Sci U S A (2000) 2.77
Politics of euthanasia in the UK. Lancet (1995) 2.75
Health, but not for all. Lancet (1992) 2.71
Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol (1996) 2.67
A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res (1998) 2.58
Configural information in facial expression perception. J Exp Psychol Hum Percept Perform (2000) 2.48
Genotype/Phenotype analysis of a photoreceptor-specific ATP-binding cassette transporter gene, ABCR, in Stargardt disease. Am J Hum Genet (1999) 2.42
A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene (2000) 2.35
Mutation of a putative mitochondrial iron transporter gene (ABC7) in X-linked sideroblastic anemia and ataxia (XLSA/A). Hum Mol Genet (1999) 2.34
Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer (2003) 2.33
Medics versus managers. Lancet (1994) 2.33
Detecting single base substitutions as heteroduplex polymorphisms. Genomics (1992) 2.26
Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res (2001) 2.25
Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood (2001) 2.25
A frame-shift mutation in the cystic fibrosis gene. Nature (1990) 2.23
The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci (2000) 2.21
A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci U S A (2000) 2.20
Congenital bilateral absence of the vas deferens. A primarily genital form of cystic fibrosis. JAMA (1992) 2.11
Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively. Am J Hum Genet (2001) 2.08
Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clin Pharmacol Ther (2011) 2.04
Euthanasia moves up the medical agenda. Lancet (1993) 2.03
UK ministers seek NICE new health efficiencies. National Institute for Clinical Effectiveness. Lancet (1998) 2.03
Regulation of c-myc transcription and mRNA abundance by serum growth factors and cell contact. J Biol Chem (1986) 2.00
HIV-1 infection in a man homozygous for CCR5 delta 32. Lancet (1997) 1.95
p53 inhibits hypoxia-inducible factor-stimulated transcription. J Biol Chem (1998) 1.94
AIDS and the Murdoch press. Lancet (1992) 1.93
Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. J Biol Chem (1998) 1.93
Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags database. Hum Mol Genet (1996) 1.90
Mapping of a gene causing familial Mediterranean fever to the short arm of chromosome 16. N Engl J Med (1992) 1.90
From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci (2001) 1.89
c-myc regulation during retinoic acid-induced differentiation of F9 cells is posttranscriptional and associated with growth arrest. Mol Cell Biol (1986) 1.85
Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression. Biochemistry (1990) 1.83
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res (1996) 1.82
A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochim Biophys Acta (2001) 1.82
Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res (2001) 1.81
Specific regulation of c-myc oncogene expression in a murine B-cell lymphoma. Proc Natl Acad Sci U S A (1984) 1.76
Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene (2011) 1.71
Genetic variants in AVPR1A linked to autism predict amygdala activation and personality traits in healthy humans. Mol Psychiatry (2008) 1.70
Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer (1999) 1.70
Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol (1994) 1.70
Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene (2007) 1.67
Medical changes and hospital beds. Lancet (1994) 1.66
Genetics of HIV-1 infection: chemokine receptor CCR5 polymorphism and its consequences. Hum Mol Genet (1999) 1.65
Tyrosine kinase oncogenes abrogate interleukin-3 dependence of murine myeloid cells through signaling pathways involving c-myc: conditional regulation of c-myc transcription by temperature-sensitive v-abl. Mol Cell Biol (1989) 1.64
Further linkage data on cystic fibrosis: the Utah Study. Am J Hum Genet (1986) 1.63
Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res (1999) 1.62
Sensitivity of single-strand conformation polymorphism and heteroduplex method for mutation detection in the cystic fibrosis gene. Hum Mol Genet (1994) 1.62
The rod photoreceptor ATP-binding cassette transporter gene, ABCR, and retinal disease: from monogenic to multifactorial. Vision Res (1999) 1.61
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer (2000) 1.60
Water transport by the Na+/glucose cotransporter under isotonic conditions. Biol Cell (1997) 1.59
Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res (1997) 1.56
The chemical defensome: environmental sensing and response genes in the Strongylocentrotus purpuratus genome. Dev Biol (2006) 1.54
Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab (2001) 1.54
Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia (2007) 1.52
Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett (1999) 1.52
Transcriptional activation of immunoglobulin alpha heavy-chain genes by translocation of the c-myc oncogene. Nature (1983) 1.51
Population and pedigree studies reveal a lack of association between the dopamine D2 receptor gene and alcoholism. JAMA (1990) 1.51
Refined linkage map of chromosome 7 in the region of the cystic fibrosis gene. Am J Hum Genet (1988) 1.48
Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst (1999) 1.46
Characterization of estrogen responsive transforming activity in human breast cancer cell lines. Cancer Res (1986) 1.44
Novel multidrug resistance reversal agents. J Med Chem (1999) 1.44